Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HypoCat
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
HypoCat is a veterinary vaccine designed to neutralize the major cat allergen, Fel d 1, within the cat itself to reduce allergic reactions in humans. Developed by Saiba Animal Health, the vaccine utilizes a virus-like particle (VLP) platform derived from the cucumber mosaic virus (CuMV-tt) which is coupled with the recombinant Fel d 1 protein. Upon subcutaneous administration, the vaccine induces the cat's immune system to produce specific neutralizing antibodies against its own Fel d 1 protein. These antibodies bind to the allergen in the cat's secretions, such as saliva and lacrimal fluid, significantly reducing the amount of active Fel d 1 shed into the environment. This innovative approach aims to alleviate symptoms for cat-allergic individuals without requiring them to take medication or rehome their pets.
- Brand names
- HypoCat
- Other names
- Fel d 1 vaccineCat allergy vaccine
Beyond the preview
Go deeper on HypoCat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HypoCat.